

Independent Auditor's report on Audit of Standalone Financial Results and Review of Half Yearly Financial Results

To
**The Board of Director of
Unihealth Hospitals Limited
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)**

Opinion

We have audited the accompanying statement of Standalone Financial Results ("the Statement") of Unihealth Hospitals Limited (hereinafter referred to as "the Company") for the year ended March 31, 2026 and reviewed the Standalone Financial Results for Half Yearly period ended March 31, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended in this regard; and;
- ii) give a true and fair view in conformity with the applicable Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit and other financial information of the Company for the Half year and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under section 143(10) of the Companies Act, 2013, as amended (“the Act”). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial results section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial results.

Management’s Responsibilities for the Standalone Financial Results

These Standalone financial results have been prepared on the basis of the Annual Standalone financial statements. The Board of Directors’ of the Company’s is responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit/loss and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (“Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act; safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors’ is responsible for overseeing the Company’s financial reporting process.

Auditor’s Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Conclude on the appropriateness of Management use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

G. P. KAPADIA & CO.

Chartered Accountants

Other Matter

The Standalone financial results include the results for the half year ended March 31, 2026 being the balancing figures between the audited figures of the full financial year 2025-26 and the unaudited published figures up to the first half year (September 30, 2025) of the current financial year, which was subject to Limited review by us. Our opinion is not modified in respect of this matter.

For G.P. Kapadia & Co.
Chartered Accountants
(Firm's Registration No.104768W)

Digitally signed by Atul Babubhai Desai
Date: 2026.05.29 19:37:12 +05'30'

Atul Desai

Partner

Membership No. 30850

Date: 29th May 2026

Place: Mumbai

UDIN: 26030850PBKGUZ4403

UNIHEALTH HOSPITALS LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491
AUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2026

	PARTICULARS	HALF YEAR ENDED			YEAR ENDED	
		31.03.2026	30.09.2025	31.03.2025	31.03.2026	31.03.2025
		Audited	Unaudited	Audited	Audited	Audited
		Refer note 1 and 7	Refer note 1	Refer note 1	Refer note 1	Refer note 1
1	Revenue from operations	367.06	286.90	200.22	653.96	356.10
2	Other income	402.94	265.95	180.43	668.89	330.96
3	Total revenue	770.00	552.85	380.65	1,322.85	687.06
4	Expenses					
	Purchases of stock in trade	75.66	-	58.84	75.66	58.84
	Changes in inventories of Finished goods, Work in progress and Stock-in-trade	-	-	-	-	-
	Employee benefits expense	89.70	87.02	83.92	176.72	162.44
	Finance costs	2.17	8.27	3.07	10.44	3.25
	Depreciation and amortization expense	11.38	12.43	14.86	23.81	28.23
	Other expenses	72.92	80.29	52.24	153.21	110.48
5	Total Expense	251.83	188.01	212.93	439.84	363.24
6	Profit/(Loss) before exceptional and Tax	518.17	364.84	167.72	883.01	323.82
7	Exceptional Items	-	-	-	-	-
8	Profit/(Loss) Before Tax	518.17	364.84	167.72	883.01	323.82
9	Tax expense					
	(1) Current tax	139.91	92.93	44.68	232.84	85.70
	(2) Short/(Excess) provision of earlier year	0.16	-	4.38	0.16	4.38
	(3) Deferred tax	1.44	(0.56)	(1.06)	0.88	(1.18)
10	Total Tax Expense	141.51	92.37	48.00	233.88	88.90
11	Profit After Tax for the period	376.66	272.47	119.72	649.13	234.92
12	Share in profit/(loss) of associates	-	-	-	-	-
13	Profit for the period	376.66	272.47	119.72	649.13	234.92
14	Other Comprehensive Income / (Expense)					
	(A) Items that will not be reclassified to profit or loss					
	a) Remeasurement Gain/(Loss) on defined benefit plans	11.68	(2.22)	(1.49)	9.46	(2.81)
	b) Income Tax relating to items that will not be reclassified to Profit and Loss	(2.94)	0.56	0.38	(2.38)	0.71
	(B) Items that will be reclassified to profit or loss					
	a) Exchange difference in translating financials of foreign operations	-	-	-	-	-
	b) Income Tax relating to items that will not be reclassified to Profit and Loss	-	-	-	-	-
	Total Other Comprehensive Income / (Expense), Net of Tax	8.74	(1.66)	(1.11)	7.08	(2.10)
15	Total Comprehensive Income for the period	385.40	270.81	118.61	656.21	232.82
16	Details of Equity Share Capital					
	Paid-up Equity Share Capital	1,570.00	1,550.00	1,540.00	1,570.00	1,540.00
	Face Value of equity share capital	Rs 10/-	Rs 10/-	Rs 10/-	Rs 10/-	Rs 10/-
	Reserves excluding revaluation reserve	-	-	-	6,362.31	5,132.10
17	Earnings per equity share:					
	(a) Basic EPS from continuing and discontinued operations	2.49	1.77	0.79	4.19	1.53
	(b) Diluted EPS from continuing and discontinued operations	2.46	1.77	0.79	4.15	1.53

NOTES:

- This is the first period for which the Company has prepared financial results in compliance with Ind AS. Prior to April 1, 2025, the Company had prepared its Financial Statement in accordance with the Accounting Standards notified under 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP).
- The Company has adopted Ind AS (Indian Accounting Standards) w.e.f April 1, 2025. The Reconciliation of Net Profit reported in accordance with Previous GAAP to total comprehensive Income in accordance with Ind AS for the year and half year ended 31st March, 2025 is given below.

Particulars	Rs. in lakhs			
	Half-Year Ended on 31st March 2025 (Audited)		Year Ended on 31st March 2025 (Audited)	
	Consolidated	Standalone	Consolidated	Standalone
Net Profit for the period under previous Indian GAAP	997.23	120.62	1514.61	233.37
Adjustments on account of:				
Employee benefit expense	1.49	1.49	2.81	2.81
Interest Income	3.20	0.19	3.38	0.37
Interest expense on security deposit	(0.16)	(0.16)	(0.32)	(0.32)
Interest expense on lease	(20.39)	-	(25.93)	-
Rent expense	64.75	-	94.18	-
Depreciation	(136.01)	-	(161.03)	-
Tax	(3.34)	(2.42)	(12.44)	(1.31)
Conversion of JV to Subsidiary on account of IND AS	907.40	-	1303.24	-
FCTR	(2.82)	-	(6.03)	-
Net Profit for the period as per IND AS	1811.35	119.72	2,712.47	234.92

- 3 The Company has adopted Ind AS (Indian Accounting Standards) w.e.f April 1, 2025. The Reconciliation of Equity as reported in accordance with Previous GAAP and in accordance with Ind AS for the year ended 31st March, 2025 is given below.

Particulars	Rs. in lakhs	
	Year Ended on 31st March 2025	
	(Audited)	
	Consolidated	Standalone
Equity as reported under previous Indian GAAP	8809.72	5,140.71
Adjustments on account of:		
Items reclassified to Other Comprehensive Income	(8.71)	(11.53)
Deferred Tax	(3.34)	2.92
Change in Control Assessment	(10.26)	
FCTR	(191.26)	
Equity for the period as per IND AS	8,596.15	5,132.10

- 4 The standalone/Consolidated financial results of the company have been prepared in, accordance with Indian Accounting standards (Ind AS) as prescribed under section 133 of the companies Act 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (LODR) Regulation, 2015. The company has also reclassified the previous figures in accordance with the requirements applicable in the current period.
- 5 The standalone financial results ("the Statement") of the Company for the Half year and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 29, 2026. The statutory auditors, have expressed an unmodified review conclusion on the standalone financial results for the Half year ended March 31, 2026 and have expressed an unmodified audit opinion on the financial results for the year ended March 31, 2026. The Statutory Auditors have conducted audit of the above mentioned half yearly financial results of March 31, 2026, as required by regulation 33 of SEBI (LODR) regulations, 2015.
- 6 Basic earnings per share are calculated by dividing the profit after Tax for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of 4 lakh number of equity share warrants amounting to Rs.604 lakhs outstanding at the end of the year for computing dilutive potential equity shares.
- 7 The Figures for half year ended 31 st March 2026 are the balancing figures between the audited figures in respect of Financial year 2025-26 and the Published unaudited figures of Half year ended september 30, 2025, which were subject to limited review.
- 8 investment in UHS Oncology Private Limited (Associate Company) amounting to Rs.0.33 Lakhs was redeemed during the year.
- 9 The company has allotted 7 Lakhs convertible warrants on 2nd May 2025 as approved by Shareholders at the Extra Ordinary General Meeting held on 9th April 2025. The company has already converted 3 lakhs warrants into equity shares during the year. The company has already converted 3 lakhs warrants into equity shares during the year. The balance 4 lakhs warrants are outstanding and the company has received the 25% of the issue price for such warrants. The warrants are convertible into equal number of equity share and the conversion option can be exercised at any time during the period of 18 months from the date of allotment of the said warrants.
- 10 The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company.
- 11 The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November, 2018.
- 12 There are no investors complaints pending as on 31 March, 2026.
- 13 Segment information is presented in the "Consolidated Financial Results" as permitted under the Ind AS 108 - 'Operating Segments'.
- 14 Figures for the previous periods /year have been regrouped ,restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation.
- 15 The proceeds from the Equity shares IPO issued during FY 23-24 was amounting to Rs 5654.88 lakhs. The object and proposed utilization of IPO Proceeds and amount utilized as on March 31, 2026 is as under:-

Object	Amount Utilized (Rs. in lakhs)
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL	1700.00
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion	290.30
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion*	237.50
Investment in our subsidiaries UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa*	1350.00
General Corporate Purpose	1093.08
Issue Expenses	814.30

* The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e, Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company.

For and on behalf of Board of
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)


Dr. Akshav M. Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 29th May 2026



UNIHEALTH HOSPITALS LIMITED
(Formerly known as Unihealth Consultancy Limited)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

AUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH 2026

(₹ in Lakhs)

Sr. No.	Particulars	As at	As at
		31-Mar-2026	31-Mar-2025
		Audited	Audited
		Refer note 1	Refer note 1
A.	ASSETS		
I	Non-Current Assets		
(a)	Property Plant and Equipment	287.35	310.90
(b)	Capital Work in Progress	-	-
(c)	Intangible Assets	2.52	3.73
(d)	Investment Property	-	-
(e)	Goodwill	-	-
(f)	Right-of-Use Assets	-	-
(g)	Financial Assets		
(i)	Investments	3,049.40	3,049.73
(ii)	Loans	3,693.26	2,593.16
(iii)	Others	5.47	5.01
(h)	Deferred Tax Assets	-	-
(i)	Other Non-current asstes	-	-
	Total Non-Current Assets	7,038.00	5,962.53
II	Current Assets		
(a)	Inventories	-	-
(b)	Financial Assets		
(i)	Investments	-	-
(ii)	Trade Receivables	456.33	290.72
(iii)	Cash and Cash Equivalents	309.98	16.34
(iv)	Bank Balance other than (iii) above	-	400.00
(v)	Loans	-	-
(vi)	Others	241.88	172.59
(c)	Current Tax Assets	-	-
(d)	Other Current Assets	130.79	196.33
(e)	Assets held for sale	-	-
	Total Current Assets	1,138.98	1,075.98
	Total Assets	8,176.98	7,038.51
B	EQUITY AND LIABILITIES		
I	Equity		
(a)	Equity Share Capital	1,570.00	1,540.00
(b)	Other Equity	6,362.31	5,132.10
	Total Equity	7,932.31	6,672.10
II	Non-Current Liabilities		
(a)	Financial Liabilities		
(i)	Borrowings	-	78.00
(ii)	Lease Liabilities	-	-
(b)	Provisions	24.17	26.16
(c)	Deferred Tax Liabilities	7.97	4.72
(d)	Others	-	-
	Total Non-Current Liabilities	32.14	108.88
III	Current Liabilities		
(a)	Financial Liabilities		
(i)	Borrowings	-	187.51
(ii)	Lease Liabilities	-	-
(iii)	Trade Payables		
	- Total Outstanding Dues of Micro Enterprises and Small Enterprises	19.76	11.19
	- Total Outstanding Dues of Creditors Other than Micro Enterprises and Small Enterprises	5.51	1.72
(iv)	Other Current Financial Liabilities	42.15	26.59
(b)	Other Current Liabilities	4.62	4.69
(c)	Provisions	140.49	25.83
	Total Current Liabilities	212.53	257.53
	Total Liabilities	244.67	366.41
	Total Equity and Liabilities	8,176.98	7,038.51

For and on behalf of Board of Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)


Dr. Akshay M. Parmar
Managing Director
DIN:01533004
Place : Mumbai
Date: 29th Mar 2026



UNIHEALTH HOSPITALS LIMITED
(Formerly known as Unihealth Consultancy Limited)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH 2026

(₹ in Lakhs)

	Particulars	For the Year ended	For the Year ended
		31st March 2026	31st March 2025
		Refer note 1	Refer note 1
A	Cash flow from operating activities		
	Net profit before tax	883.01	323.82
	Adjustments for:		
	Depreciation/amortization	23.81	28.23
	Finance Cost	10.44	3.25
	Foreign exchange (gain)/Loss	(103.70)	(45.19)
	Interest on FD	(5.31)	(82.87)
	Interest on Loan given	(152.48)	(196.31)
	Operating profit before working capital changes	655.77	30.93
	Changes in assets and liabilities:		
	Increase / (decrease) in Trade Payables	12.35	10.08
	Increase / (Decrease) in Other Current Liabilities	(0.07)	0.86
	Increase / (decrease) in Provisions	122.14	3.38
	Increase / (decrease) in Other Financial Liabilities	15.56	39.93
	(Increase) / decrease in Other Financial Assets and Other Current Assets	(4.22)	(52.17)
	(Increase) / Decrease in Trade Receivables	(165.61)	(29.94)
	(Increase)/Decrease in Current Tax assets	-	0.01
	Cash (used in)/ generated from operating activities	635.92	3.08
	Income tax paid	(233.00)	(85.70)
	Net cash from/ (used in) from operating activities (A)	402.92	(82.62)
B	Cash flow from Investing activities		
	Proceeds/(investments) in fixed deposits & shares (net)	0.33	(1,212.37)
	Purchase of property, plant and equipment	0.94	(34.10)
	Loans (advanced)/received to/from Subsidiaries & Associates	(1,100.10)	(1,139.63)
	Interest received	5.31	82.87
	Interest on loan given	152.48	196.31
	Maturity proceeds of fixed deposits	400.00	1,300.00
	Net cash from/ (used in) from investing activities (B)	(541.04)	(806.92)
C	Cash flow from Financing activities		
	Proceeds from Issuance of Share Capital	453.00	-
	Proceeds from issue of Share warrants	151.00	-
	Proceeds/ (Repayment) of Borrowings	(265.50)	(64.46)
	Foreign exchange (gain)/Loss	103.70	9.31
	Finance cost	(10.44)	(3.25)
	Net cash from / (used in) from financing activities (C)	431.76	(58.40)
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	293.64	(947.94)
	Cash and cash equivalents at the beginning of the year	16.34	964.28
	Cash and cash equivalents at the end of the year	309.98	16.34

For and on behalf of Board of Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)


Dr. Akshay M. Parmar
Managing Director
DIN:01533004
Place: Mumbai
Date: 29th May 2026

